Edition:
India

Teva Pharmaceutical Industries Ltd (TEVA.N)

TEVA.N on New York Stock Exchange

7.91USD
1:30am IST
Change (% chg)

$0.08 (+1.02%)
Prev Close
$7.83
Open
$7.87
Day's High
$8.00
Day's Low
$7.77
Volume
3,588,094
Avg. Vol
3,247,249
52-wk High
$25.96
52-wk Low
$7.67

Latest Key Developments (Source: Significant Developments)

FDA Says Teva Expanding Its Voluntary Recall To Include 7 Additional Lots Of Losartan Potassium Tablets
Wednesday, 12 Jun 2019 

June 12 (Reuters) - U.S. Food and Drug Administration::FDA SAYS TEVA IS EXPANDING ITS VOLUNTARY RECALL TO INCLUDE SEVEN ADDITIONAL LOTS OF LOSARTAN POTASSIUM TABLETS LABELED BY GOLDEN STATE MEDICAL SUPPLY.  Full Article

FDA Says Teva Pharmaceuticals USA Expands Voluntary Nationwide Recall Of Losartan Potassium
Tuesday, 11 Jun 2019 

June 11 (Reuters) - U.S. Food and Drug Administration::TEVA PHARMACEUTICALS USA, INC. EXPANDS VOLUNTARY NATIONWIDE RECALL OF LOSARTAN POTASSIUM TO 50 MG AND 100 MG TABLETS USP, SOLD EXCLUSIVELY TO GOLDEN STATE MEDICAL SUPPLY, INC..FDA - TEVA PHARMACEUTICALS USA, EXPANDED VOLUNTARY CONSUMER-LEVEL RECALL ORIGINALLY INITIATED ON APRIL 25 IN U.S. OF LOSARTAN POTASSIUM TABLETS.FDA - EXPANDED TEVA RECALL INCLUDES 6 LOTS OF BULK LOSARTAN POTASSIUM USP TABLETS DUE TO DETECTION OF IMPURITY, N-NITROSO-N-METHYL-4-AMINOBUTYRIC ACID.  Full Article

Teva Announces Launch Of Generic Version Of Ranexa Extended-Release Tablets In U.S.
Tuesday, 28 May 2019 

May 28 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES LAUNCH OF A GENERIC VERSION OF RANEXA® (RANOLAZINE) EXTENDED-RELEASE TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES - LAUNCH OF A GENERIC VERSION OF RANEXA (RANOLAZINE) EXTENDED-RELEASE TABLETS, 500 MG AND 1000 MG, IN U.S..  Full Article

Teva Announces Update On Fremanezumab Clinical Development For Use In Episodic Cluster Headache
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES UPDATE ON FREMANEZUMAB CLINICAL DEVELOPMENT FOR USE IN EPISODIC CLUSTER HEADACHE.TEVA PHARMACEUTICAL - PROVIDED AN UPDATE THAT COMPANY IS DISCONTINUING CLINICAL DEVELOPMENT PROGRAM FOR USE OF FREMANEZUMAB IN CLUSTER HEADACHES.TEVA PHARMACEUTICAL INDUSTRIES LTD - DISCONTINUING ENFORCE PHASE III CLINICAL TRIAL PROGRAM.TEVA PHARMACEUTICAL INDUSTRIES LTD - CONTINUES TO EXPLORE OTHER USES FOR FREMANEZUMAB, INCLUDING TREATMENT OF POST-TRAUMATIC HEADACHE.TEVA PHARMA - STUDY'S PRIMARY ENDPOINT IS UNLIKELY TO BE MET.  Full Article

Teva Announces Launch Of A Generic Version Of Vesicare Tablets In U.S.
Monday, 22 Apr 2019 

April 22 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA ANNOUNCES LAUNCH OF A GENERIC VERSION OF VESICARE® (SOLIFENACIN SUCCINATE) TABLETS IN THE UNITED STATES.TEVA PHARMACEUTICAL INDUSTRIES LTD - ANNOUNCED LAUNCH OF A GENERIC VERSION OF VESICARE (SOLIFENACIN SUCCINATE) TABLETS, 5 MG AND 10 MG, IN U.S..  Full Article

Teva Pharmaceuticals USA Inc. Receives Final FDA Approval To Market Generic Naloxone Nasal Spray
Friday, 19 Apr 2019 

April 19 (Reuters) - FDA::FDA APPROVES FIRST GENERIC NALOXONE NASAL SPRAY TO TREAT OPIOID OVERDOSE.FDA - TEVA PHARMACEUTICALS USA INC. HAS RECEIVED FINAL FDA APPROVAL TO MARKET GENERIC NALOXONE NASAL SPRAY.  Full Article

Rovi To Market Teva’s Osteoporosis Treatment For Adults In Spain
Thursday, 11 Apr 2019 

April 11 (Reuters) - Rovi ::ROVI WILL MARKET TEVA’S OSTEOPOROSIS TREATMENT FOR ADULTS TETRIDAR IN SPAIN.IS EXPECTED TO BEGIN MARKETING OF TETRIDAR IN SPAIN IN Q3 2019.  Full Article

Teva's Ajovy Receives EU Approval Offering Patients The First And Only Anti-Cgrp Treatment
Monday, 1 Apr 2019 

April 1 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA’S AJOVY® RECEIVES EU APPROVAL OFFERING PATIENTS THE FIRST AND ONLY ANTI-CGRP TREATMENT WITH BOTH QUARTERLY AND MONTHLY DOSING FOR THE PROPHYLAXIS OF MIGRAINE IN ADULTS.TEVA PHARMACEUTICAL INDUSTRIES LTD - EC DECISION IS APPLICABLE TO ALL 28 EU MEMBER STATES PLUS ICELAND, NORWAY AND LIECHTENSTEIN.  Full Article

Teva Says Received Favorable Response From European Patent Office Regarding Copaxone 40Mg
Monday, 1 Apr 2019 

April 1 (Reuters) - Teva Pharmaceutical Industries Ltd ::TEVA'S COPAXONE® 40MG - FAVORABLE RESPONSE FROM EUROPEAN PATENT OFFICE.OPPOSITION DIVISION WILL ISSUE ITS WRITTEN UNDERLYING RATIONALE ON DECISION WITHIN A FEW MONTHS.  Full Article

Novo Nordisk Settles U.S. Patent Litigation Case On Victoza With Teva
Monday, 18 Mar 2019 

March 18 (Reuters) - Novo Nordisk A/S ::REG-NOVO NORDISK SETTLES U.S. PATENT LITIGATION CASE ON VICTOZA® (LIRAGLUTIDE) WITH TEVA.SAYS TEVA IS LICENSED TO LAUNCH A GENERIC VERSION OF VICTOZAAS OF 22 DECEMBER 2023.UNDER CERTAIN CIRCUMSTANCES TEVA COULD LAUNCH A GENERIC VERSION OF VICTOZA(®) EARLIER, BUT NOT BEFORE 22 MARCH 2023, UNLESS VICTOZA(®) PATENTS ARE NO LONGER IN FORCE OR THERE IS ANOTHER GENERIC VERSION OF VICTOZA(®) ON MARKET.SAYS IF NOVO NORDISK IS GRANTED SIX MONTHS PAEDIATRIC EXTENSION FOR VICTOZA(®), ALL ABOVE-MENTIONED TIMELINES WILL BE EXTENDED BY SIX MONTHS.SAYS - AGREEMENT IS SUBJECT TO REVIEW BY US FEDERAL TRADE COMMISSION AND US DEPARTMENT OF JUSTICE.  Full Article

Photo

Oklahoma judge approves Teva's $85 million opioid settlement

An Oklahoma judge on Monday approved a revised $85 million settlement with Teva Pharmaceutical Industries Ltd resolving claims by the state's attorney general that the drugmaker helped fuel the U.S. opioid epidemic.